Evidence map›Paper›PMID 33277782›Full record

ArticleJournal of cellular and molecular medicine2021

EZH2 is a potential prognostic predictor of glioma.

Yi-Nan Chen, Shi-Qiang Hou, Rui Jiang, Jun-Long Sun, Chuan-Dong Cheng, Zhong-Run Qian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Tumor heterogeneity and resistance in glioblastoma: the role of stem cells.Apoptosis : an international journal on programmed cell death · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yi-Nan ChenDepartment of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, Hefei, China.ORCID 0000-0001-8488-9246
Shi-Qiang HouDepartment of Neurosurgery, Chuzhou Clinical College of Anhui Medical University, The First People's Hospital Chuzhou, Chuzhou, China.
Rui JiangJiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair and Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong, China.
Jun-Long SunDepartment of Neurosurgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hosipital, Shanghai, China.
Chuan-Dong ChengDepartment of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, Hefei, China.
Zhong-Run QianDepartment of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, Hefei, China.
University of Science and Technology of China · CNAnhui Medical University · CNNantong University · CNShanghai Jiao Tong University · CN

Funding

Fundamental Research Funds for the Central Universities WK9110000032Fundamental Research Funds for the Central Universities WK9110000035Fundamental Research Funds for the Central Universities WK9110000069National Natural Science Foundation of China 81803041Natural Science Foundation of Anhui Province 1808085QH287Science and Technology Project grant from Anhui Province 1508085QH184Science and Technology Project grant from Anhui Province 201904a07020098
6 · The paper itself

Abstract

The enhancer of zeste homologue 2 (EZH2) is a histone H3 lysine 27 methyltransferase that promotes tumorigenesis in a variety of human malignancies by altering the expression of tumour suppressor genes. To evaluate the prognostic value of EZH2 in glioma, we analysed gene expression data and corresponding clinicopathological information from the Chinese Glioma Genome Atlas, the Cancer Genome Atlas and GTEx. Increased expression of EZH2 was significantly associated with clinicopathologic characteristics and overall survival as evaluated by univariate and multivariate Cox regression. Gene Set Enrichment Analysis revealed an association of EZH2 expression with the cell cycle, DNA replication, mismatch repair, p53 signalling and pyrimidine metabolism. We constructed a nomogram for prognosis prediction with EZH2, clinicopathologic variables and significantly correlated genes. EZH2 was demonstrated to be significantly associated with several immune checkpoints and tumour-infiltrating lymphocytes. Furthermore, the ESTIMATE and Timer Database scores indicated correlation of EZH2 expression with a more immunosuppressive microenvironment for glioblastoma than for low grade glioma. Overall, our study demonstrates that expression of EZH2 is a potential prognostic molecular marker of poor survival in glioma and identifies signalling pathways and immune checkpoints regulated by EHZ2, suggesting a direction for future application of immune therapy in glioma.

Indexed as

Brain NeoplasmsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticGliomaHumansImmunityNomogramsPrognosisSignal TransductionSurvival AnalysisTumor MicroenvironmentEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanEZH2gliomaimmunityoverall survival

Identifiers

PMID33277782
PMCPMC7812280
OpenAlexW3108788046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.